General Information of Drug (ID: DMD157S)

Drug Name
Montelukast
Synonyms
Brondilat; Montair; Singular; Apxi toxin; MK 0476; Brondilat (TN); MK-0476; Montelukast (INN); Montelukast [INN:BAN]; Singulair (TN); Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
Indication
Disease Entry ICD 11 Status REF
Allergic asthma CA23.0 Approved [1]
Allergic rhinitis CA08.0 Approved [1]
Asthma CA23 Approved [2]
Intrinsic asthma N.A. Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2/3 [3]
Therapeutic Class
Antiasthmatic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 586.2
Logarithm of the Partition Coefficient (xlogp) 7.7
Rotatable Bond Count (rotbonds) 12
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
62% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.68 mL/min/kg [6]
Elimination
0.2% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 hours [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.28489 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.002% [6]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.15 L/kg [6]
Chemical Identifiers
Formula
C35H36ClNO3S
IUPAC Name
2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
Canonical SMILES
CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O
InChI
InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1
InChIKey
UCHDWCPVSPXUMX-TZIWLTJVSA-N
Cross-matching ID
PubChem CID
5281040
ChEBI ID
CHEBI:50730
CAS Number
158966-92-8
DrugBank ID
DB00471
TTD ID
D00QET
VARIDT ID
DR00382
INTEDE ID
DR1111
ACDINA ID
D00445
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukotriene CysLT1 receptor (CYSLTR1) TTGKOY9 CLTR1_HUMAN Antagonist [8]
HUMAN cysteinyl leukotriene receptor (CysLTR) TTSB6CA CLTR1_HUMAN ; CLTR2_HUMAN Antagonist [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [10]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [13]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [12]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Montelukast
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Zafirlukast DMHNQOG Moderate Decreased metabolism of Montelukast caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [15]
Coadministration of a Drug Treating the Disease Different from Montelukast (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Nateglinide DMLK2QH Moderate Decreased metabolism of Montelukast caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [15]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Montelukast caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [16]
Mitotane DMU1GX0 Moderate Increased metabolism of Montelukast caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [16]
Metronidazole DMTIVEN Moderate Decreased metabolism of Montelukast caused by Metronidazole mediated inhibition of CYP450 enzyme. Amoebiasis [1A36] [15]
Voriconazole DMAOL2S Moderate Decreased metabolism of Montelukast caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [15]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Montelukast caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [16]
Tucatinib DMBESUA Moderate Decreased metabolism of Montelukast caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [17]
Alpelisib DMEXMYK Moderate Increased metabolism of Montelukast caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
Tamoxifen DMLB0EZ Moderate Decreased metabolism of Montelukast caused by Tamoxifen mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Toremifene DMQYUWG Moderate Decreased metabolism of Montelukast caused by Toremifene mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Phenylbutazone DMAYL0T Moderate Decreased metabolism of Montelukast caused by Phenylbutazone mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [15]
Mifepristone DMGZQEF Moderate Decreased metabolism of Montelukast caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [19]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Montelukast caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [20]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Montelukast caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [15]
MK-8228 DMOB58Q Moderate Decreased metabolism of Montelukast caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [15]
Primidone DM0WX6I Moderate Increased metabolism of Montelukast caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [16]
Felbamate DM1V5ZS Moderate Increased metabolism of Montelukast caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [16]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Montelukast caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [16]
Cenobamate DM8KLU9 Moderate Increased metabolism of Montelukast caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [16]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Montelukast caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [16]
Phenobarbital DMXZOCG Moderate Increased metabolism of Montelukast caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [16]
Carbamazepine DMZOLBI Moderate Increased metabolism of Montelukast caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [16]
Tazemetostat DMWP1BH Moderate Increased metabolism of Montelukast caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [16]
Miconazole DMPMYE8 Moderate Decreased metabolism of Montelukast caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [15]
Ripretinib DM958QB Moderate Decreased metabolism of Montelukast caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [15]
Sulfinpyrazone DMEV954 Moderate Decreased metabolism of Montelukast caused by Sulfinpyrazone mediated inhibition of CYP450 enzyme. Gout [FA25] [15]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Montelukast caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [15]
Rifampin DMA8J1G Moderate Increased metabolism of Montelukast caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [21]
Rifapentine DMCHV4I Moderate Increased metabolism of Montelukast caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [16]
Delavirdine DM3NF5G Moderate Decreased metabolism of Montelukast caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Efavirenz DMC0GSJ Moderate Decreased metabolism of Montelukast caused by Efavirenz mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Etravirine DMGV8QU Moderate Decreased metabolism of Montelukast caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Gemfibrozil DMD8Q3J Moderate Decreased metabolism of Montelukast caused by Gemfibrozil mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [15]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Montelukast caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [15]
Teriflunomide DMQ2FKJ Moderate Decreased metabolism of Montelukast caused by Teriflunomide mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [15]
PF-06463922 DMKM7EW Moderate Increased metabolism of Montelukast caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [16]
Selpercatinib DMZR15V Moderate Decreased metabolism of Montelukast caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [15]
IPI-145 DMWA24P Moderate Decreased metabolism of Montelukast caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [22]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Montelukast caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [15]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Montelukast caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [16]
Exjade DMHPRWG Moderate Decreased metabolism of Montelukast caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [15]
Rifabutin DM1YBHK Moderate Increased metabolism of Montelukast caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [16]
Imatinib DM7RJXL Moderate Decreased metabolism of Montelukast caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [15]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Montelukast caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [15]
Abametapir DM2RX0I Moderate Decreased metabolism of Montelukast caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [23]
Lefamulin DME6G97 Moderate Decreased metabolism of Montelukast caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [24]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Montelukast caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [15]
Enzalutamide DMGL19D Moderate Increased metabolism of Montelukast caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [16]
Bosentan DMIOGBU Moderate Increased metabolism of Montelukast caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [16]
Dexamethasone DMMWZET Moderate Increased metabolism of Montelukast caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [16]
Nafcillin DMN9RPO Moderate Increased metabolism of Montelukast caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [16]
Leflunomide DMR8ONJ Moderate Decreased metabolism of Montelukast caused by Leflunomide mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [15]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Montelukast caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [25]
Sulfamethizole DMGCHDS Moderate Decreased metabolism of Montelukast caused by Sulfamethizole mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [15]
Elagolix DMB2C0E Moderate Increased metabolism of Montelukast caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [16]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Montelukast caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [15]
⏷ Show the Full List of 56 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Aspartame E00402 134601 Flavoring agent
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Lactic acid E00020 612 Acidulant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sucralose E00370 71485 Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Carmellose sodium E00625 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Edetate disodium E00186 8759 Complexing agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 32 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Montelukast 4 mg tablet 4 mg Chewable Tablet Oral
Montelukast 5 mg tablet 5 mg Chewable Tablet Oral
Montelukast 10 mg tablet 10 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Montelukast FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3340).
3 The COvid-19 Symptom MOntelukast Trial (COSMO)
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94.
9 As a potential treatment of COVID-19: Montelukast. Med Hypotheses. 2020 May 11;142:109828.
10 Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. J Clin Pharmacol. 2013 Nov;53(11):1186-93.
11 Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol. 2011 May;51(5):751-60.
12 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13 In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab Dispos. 2015 Dec;43(12):1905-16.
14 Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem. 2008 Jun 20;283(25):17227-37.
15 Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT "Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast." Clin Pharmacol Ther (2010):. [PMID: 20592724]
16 Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA.
17 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
18 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
19 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
20 Cerner Multum, Inc. "Canadian Product Information.".
21 Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6. [PMID: 6953748]
22 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
23 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
24 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
25 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.